Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for Buerger's disease critical ischemia
2021-005723-20Phase 4Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in Buerger disease (TAO), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Feasibility and tolerance of BoNT-A injections. Started Nov 2021; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
Buerger disease (TAO)
Beyond the preview
Go deeper on 2021-005723-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005723-20.